ILMN Illumina, Inc.
Trend channel, buy level and 3-month target. Information only, not financial advice.
Inside the channel · 12-month channel rising
Price is between the lines.
- 3-year channel
- US$161.56 – US$183.64 · rising, +15% a year
- 12-month channel read from
- US$144.02 – US$339.31 · rising, more than +100% a year
- Price in channel
- 47% (0% = floor, 100% = ceiling)
- Ceiling overhead
- US$339.31
- Turns bearish below
- US$144.02
Price history, with the path projected 3 months forward
Updated 7:30 AM ET (3 h ago)
- Daily close
- Upper trend line (3 years)
- Lower trend line (3 years)
- The same lines over the last 12 months
- Dashed after today: projected 3 months
- Our buy
- Our target
Our target
No published call: price has closed 28.5% clear above the channel, so the fitted lines no longer describe where it is Levels below are for reference only.
Buy at or below
US$161.60
level as at 1 Nov 2026
Our target
US$185.69
by 2 Nov 2026
Projected move
14.9%
gross, before costs
Price is at or past our target.
- Upper line touches
- 6
- Lower line touches
- 5
- Fit confidence
- 37%
- Fitted
- 1 Nov 2026
Company information
About Illumina, Inc.
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Jacob Thaysen
- Employees
- 8,600
- Country
- US
Scorecard
Our own scores from the fundamentals below (not Morningstar ratings).
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$40.03B
- Enterprise value
- —
- Beta
- 1.42
- Avg volume
- 2.52M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 88-309.35
- Exchange
- NASDAQ
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted to past swing highs and lows and may not continue. Information only, not financial advice.